This page contains exclusive content for the member of the following sections: TTS. Log in to view.
Presenter: Jane, Gralla, Aurora, United States
Authors: Gralla J., Wiseman A.
INDUCTION IMMUNOSUPPRESSION
J. Gralla1, A. Wiseman2
1Pediatrics, University of Colorado Denver, Denver/UNITED STATES OF AMERICA, 2Division Of Renal Diseases And Hypertension, University of Colorado Denver, Denver/UNITED STATES OF AMERICA
Body: Introduction: The use of IL2-RA induction therapy has gained favor due to an excellent safety profile and improved outcomes in randomized trials using CsA-based immunosuppression. However, there have been no large randomized trials or retrospective analyses examining the effect of IL2-RA induction vs. no induction using TAC/MMF-based therapy. Methods: Using the SRTR database, we performed a retrospective analysis of 28,686 adult first kidney transplant recipients from 2000-2008 who received TAC/MMF and Prednisone as initial immunosuppression and received IL2-RA (either basiliximab or daclizumab with no other induction agents, n=14,482) or no induction therapy (n=14,204). Primary endpoints were acute rejection at one year and graft survival at 1 and 3 years. Baseline donor, recipient, and transplant factors that have been shown to impact rejection and graft survival were compared among groups and analyzed for potential confounding effects. Results: The 1-year acute rejection rate overall was 12.3%, with acute rejection rates of 11.6% in those who received IL2-RA vs. 13.0% in those receiving no induction (p<0.001). Graft survival rates were not impacted by the use of IL2-RA (Table 1).Table 1: Unadjusted acute rejection at 1 year and graft survival rates in patients on TAC/MMF/Prednisone-based immunosuppression, by IL2-RA vs. no induction
IL2-RA | No Induction | p-value | ||
| 11.6% | 13.0% | <0.001 | |
Graft survival at 1 year | 95.7% | 95.8% | 0.93 | |
Graft survival at 3 years | 87.5% | 87.8% | 0.50 |
Disclosure: All authors have declared no conflicts of interest.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada